CD19 and B-cell non-Hodgkin lymphoma: By now, two studies showed the efficacy of such a therapeutic concept comparable to the efficacy of CD19-directed CAR-T cells in controlling tumor growth and prolonging survival in xenograft models using human B cell lymphoma cell lines [85], as well as PDX models of NHL [75].